0.56
+2.95%
Close of 9 Nov 2026, in PLN
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Adiuvo Investments SA W Restrukturyzacji
Its shares trade on GPW under the ticker ADV.WA. It has been listed since 27 May 2015. In the fiscal year to 31 December 2025, it reported a net loss of PLN 1.6m. At that date it held total assets of PLN 10.6m and shareholders' equity of −PLN 35.0m.
Adiuvo Investment SA provides financial services. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2015-05-27. The firm focuses on the selection, development, financing and commercialization of biomedical projects on the international market. By providing intellectual property protection, technology validation in clinical trials and obtaining certificates allowing products to market, Adiuvo Investments SA is able to commercialize projects in diverse business model and internationally. The firm is looking for and invests in projects in the segments of the nutraceutical, medical devices and the digital health. Its business portfolio encompasses Airway Medix, Algae Labs, Carocelle, Cambridge Chocolate Technology, Endomedical, Esthechoc, Glia, Joint Polish Investment Fund, Marmar Investment, Nanoxide and Peptaderm.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Financials
- Industry
- Capital Markets
- Listed since
- 27 May 2015
- Employees
- 8
- Website
- adiuvoinvestments.com ↗
Leadership
Pay as last reported
- Mr. Marek OrlowskiChairman of the Management Board, since 2013PLN 495,000
- Mr. Krzysztof LaskowskiIndependent Deputy Chairman Supervisory of the Board, since 2021PLN 2,400
- Ms. Anna Aranowska-BablokMember of the Management BoardPLN 243,000
- Mr. Przemyslaw CipykIndependent Member of the Supervisory Board
- Mr. Pawel NaumanIndependent Member of the Supervisory BoardPLN 2,000
- Dr. Boguslaw UlijaszIndependent Member of the Supervisory Board
- Mr. Wojciech BablokMember of the Supervisory Board
- Mr. Jerzy LopatynskiMember of the Supervisory Board
- Mr. Emil TomaszewskiMember of the Supervisory Board
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Adiuvo Investments SA focuses on biomedical projects in the international market.
- The company employs eight full-time staff members in Warsaw, Poland.
- Adiuvo Investments SA provides intellectual property protection for its portfolio.
Weaknesses
- The firm has only eight employees, limiting operational capacity significantly.
- Adiuvo Investments SA is headquartered in Warsaw, which may restrict local reach.
- The company went public in 2015, indicating a mature but small scale.
Opportunities
- Adiuvo Investments SA invests in the growing nutraceutical segment globally.
- The firm targets medical devices, a high-growth area for innovation.
- Digital health projects offer new avenues for commercialization and expansion.
Threats
- Competition in the biomedical sector is intense and rapidly evolving.
- Regulatory changes in clinical trials could delay product commercialization efforts.
- Economic fluctuations may impact investment in early-stage biomedical projects.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.